Xeris Biopharma Holdings, Inc. (XERS)
16.99
+0.19
(+1.13%)
USD |
NASDAQ |
Nov 18, 16:00
17.02
+0.03
(+0.18%)
After-Hours: 20:00
Xeris Biopharma Holdings Enterprise Value : 3.162B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 3.162B |
| November 16, 2026 | 3.144B |
| November 13, 2026 | 3.137B |
| November 12, 2026 | 3.135B |
| November 11, 2026 | 3.111B |
| November 10, 2026 | 2.985B |
| November 09, 2026 | 2.991B |
| November 06, 2026 | 2.870B |
| November 05, 2026 | 2.483B |
| November 04, 2026 | 2.005B |
| November 03, 2026 | 1.985B |
| November 02, 2026 | 1.952B |
| October 30, 2026 | 2.050B |
| October 29, 2026 | 2.058B |
| October 28, 2026 | 2.038B |
| October 27, 2026 | 2.003B |
| October 26, 2026 | 1.959B |
| October 23, 2026 | 1.957B |
| October 22, 2026 | 2.078B |
| October 21, 2026 | 2.064B |
| October 20, 2026 | 2.127B |
| October 19, 2026 | 2.094B |
| October 16, 2026 | 1.977B |
| October 15, 2026 | 1.933B |
| October 14, 2026 | 1.879B |
| Date | Value |
|---|---|
| October 13, 2026 | 1.957B |
| October 12, 2026 | 2.005B |
| October 09, 2026 | 2.008B |
| October 08, 2026 | 1.955B |
| October 07, 2026 | 1.941B |
| October 06, 2026 | 1.933B |
| October 05, 2026 | 1.944B |
| October 02, 2026 | 1.753B |
| October 01, 2026 | 1.784B |
| September 30, 2026 | 1.840B |
| September 29, 2026 | 1.900B |
| September 28, 2026 | 1.874B |
| September 25, 2026 | 1.747B |
| September 24, 2026 | 1.721B |
| September 23, 2026 | 1.671B |
| September 22, 2026 | 1.683B |
| September 21, 2026 | 1.695B |
| September 18, 2026 | 1.591B |
| September 17, 2026 | 1.584B |
| September 16, 2026 | 1.518B |
| September 15, 2026 | 1.468B |
| September 14, 2026 | 1.482B |
| September 11, 2026 | 1.461B |
| September 10, 2026 | 1.499B |
| September 09, 2026 | 1.506B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 6.579B |
| MBX Biosciences, Inc. | 2.158B |
| ANI Pharmaceuticals, Inc. | 1.774B |
| Corcept Therapeutics, Inc. | 7.301B |
| Veru, Inc. | 13.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.29M |
| Revenue (Quarterly) | 107.22M |
| Total Expenses (Quarterly) | 95.94M |
| EPS Diluted (Quarterly) | 0.0594 |
| Gross Profit Margin (Quarterly) | 85.88% |
| Profit Margin (Quarterly) | 10.53% |
| Earnings Yield | -0.27% |
| Operating Earnings Yield | 1.53% |
| Normalized Earnings Yield | 0.4609 |